Joseph C. Papa has more than 35 years of experience in the pharmaceutical, health care and specialty pharmaceutical industries, including more than 20 years of branded prescription drug experience.
Before joining Bausch + Lomb, Mr. Papa was the Chief Executive Officer and Chairman of the Board of Bausch Health Companies Inc. ("Bausch Health") from 2016 to 2022. Previously, he was the Chief Executive Officer of the Perrigo Company from 2006 to 2016. He also served as Chairman and Chief Executive Officer of Cardinal Health's Pharmaceutical Technologies and Services business unit from 2004 to 2006. Prior to that, he was President and Chief Operating Officer for Watson Pharmaceuticals from 2001 to 2004, President of Global Country Operations for Pharmacia's North American business from 2000 to 2001 and President of Searle's U.S. Operations from 1997 to 2000. Before that, he served in various general management, sales, marketing and R&D positions during his 15-year career at Novartis Pharmaceuticals Corporation from 1983 to 1997. He led teams that successfully launched several blockbuster pharmaceutical products, including Lotrel, Diovan and Celebrex, and he is the patent holder for a cardiovascular combination treatment containing Amlodipine and Benazepril.
In 2014, Harvard Business Review ranked Mr. Papa 47th on its "2014 Best Performing CEOs in the World." list. He was also recognized on Israel-based Calcalist magazine's "Best Chief Executive Officer for the Year" list for 2013 and 2014. Additionally, he was named one of the World's Best CEOs by Barron's in 2012, which noted Perrigo "generated one of the best shareholder returns in the S&P 500 in the past five years."
Mr. Papa also serves as Lead Independent Director and Chairman of the Compensation Committee for Prometheus Biosciences, and as a member of the Board of Directors of Candel Therapeutics. He is a past member of the UConn Foundation Board of Directors and the Smith & Nephew Board of Directors, where he served as Chairman of the Remuneration Committee.
Mr. Papa holds a Bachelor of Science in Pharmacy from the University of Connecticut and an MBA from Northwestern University's Kellogg Graduate School of Management. In 2012, he received an Honorary Doctor of Science degree from the University of Connecticut's School of Pharmacy.
As General Counsel, Christina Ackermann is responsible for worldwide Legal Affairs, Compliance, Global Security and Enterprise Risk Management, and also serves as President, Global Ophthalmic Pharmaceuticals covering the United States, Canada, APAC and Latin America.
Prior to Bausch + Lomb, she was the Executive Vice President, General Counsel of Bausch Health from 2016 to 2022. She was also named Head of Commercial Operations for Bausch Health in 2020.
Previously, Ms. Ackermann was part of the Novartis group of companies for 14 years, serving ultimately as Senior Vice President, General Counsel at Alcon, where she was responsible for the legal, intellectual property and compliance functions. Prior to that, she was Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis from 2007 to 2012. She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics, and assumed the role of Head, Legal General Medicine, in 2005.
Earlier in her career, Ms. Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals and in private practice, where she focused on Securities and Mergers & Acquisitions.
Ms. Ackermann serves on the board of Graybug Vision, Inc. since August 2021, and is chairman of the Nominating and Corporate Governance Committee and is a member of the Compensation Committee. Additionally, Ms. Ackermann serves on the Advisory Board of the American Glaucoma Society Foundation.
For her undergraduate studies, Christina attended York University, Toronto, Canada, focusing initially on Fine Arts and later moving into Mathematics and Political Science. She also attended Queen's University, Kingston, Canada, where she obtained her LL.B., and King's College at the University of London, UK, where she received a Post Graduate Diploma in E.C. Competition Law.
Sam Eldessouky is responsible for overseeing all of the company’s finance functions, including controllership, tax, treasury and financial planning and analysis, as well as business development and IT.
Prior to Bausch + Lomb, Mr. Eldessouky was the Executive Vice President and Chief Financial Officer of Bausch Health from 2021 to 2022 and Controller and Chief Accounting Officer from 2016 to 2021.
Previously, Mr. Eldessouky served as Senior Vice President, Controller and Chief Accounting Officer for Tyco International plc. During his tenure at Tyco, he played a significant role in the wholesale turnaround of Tyco's business. He also played a key role in executing the spinoffs of Covidien and Tyco Electronics in 2006 and ADT NA and Flow Control in 2012. Prior to that, Mr. Eldessouky spent 10 years at PricewaterhouseCoopers (PwC), where he held several roles of increasing responsibility and served in PwC's National Office, providing technical accounting guidance on complex accounting matters.
Mr. Eldessouky has a Bachelor of Science in Accountancy from Ain Shams University and a Master's degree in Accounting and Finance from the University of Liverpool. He is a Certified Public Accountant and Chartered Global Management Accountant. He served as a member of the Board of Trustees of Financial Executives Research Foundation and Financial Executives International. Additionally, he served as a member of the Global Preparers Forum, an external advisory body to the International Accounting Standards Board, from 2007 to 2013.
For nearly three decades, Dennis Asharin has worked in manufacturing and supply chain functions within the pharmaceutical and food industries.
At Bausch + Lomb, Mr. Asharin is responsible for the company’s end-to-end Supply Chain, which includes Manufacturing, Planning, Engineering, Technology Operations, Procurement and Environmental, Health, Safety and Sustainability functions.
Before joining Bausch + Lomb, Mr. Asharin was part of Bausch Health for 15 years from 2007 to 2022, most recently serving as Chief Global Manufacturing and Supply Chain Officer. Prior to Bausch Health, Mr. Asharin spent 18 years at ConAgra foods in multiple operations positions with increasing responsibility.
Mr. Asharin has a Bachelor of Science in Microbiology, as well as multiple certifications in Manufacturing Processing and Lean Implementation.
Joseph Gordon has more than two decades of experience in the consumer health care industry where he has held various leadership positions of increasing responsibility. He first joined
Previously, Mr. Gordon led large sales and marketing organizations at Wyeth and Pfizer with responsibility for brands that included Advil and Centrum.
Mr. Gordon has a Bachelor of Science in Economics from Rutgers University.
Yehia Hashad is an ophthalmologist and retinal specialist with more than 25 years of leadership experience in various ophthalmology global research and development roles, including his current role as the Executive Vice President of Research & Development and Chief Medical Officer at Bausch + Lomb.
Most recently, Dr. Hashad was with Allergan/AbbVie where he served as Senior Vice President and Head of R&D for Allergan Aesthetics from 2020 through August 2021. There, he oversaw the development of more than 40 programs that spanned pharmaceutical products, fillers, reconstructive surgery, devices and consumer skin care. From 2010 until Allergan's acquisition by AbbVie in 2020, Dr. Hashad held a number of executive R&D positions at Allergan, including Senior Vice President and Head of Global Clinical Development; Vice President and Global Head of Clinical Development, Ophthalmology, Dermatology and Medical Aesthetics; and Vice President and Global Head of the Ophthalmology and Retina therapeutic areas.
Prior to Allergan, Dr. Hashad spent five years with Novartis Pharma AG, where he served as a Global Medical Director for age-related macular degeneration-related treatments Visudyne® and Lucentis® and as a Medical Director, Ophthalmology, for the European region. From 1996 to 2005, he held positions of increasing responsibility at T3A Pharma Group.
Dr. Hashad obtained his Master of Science in Medical and Surgical Ophthalmology from Cairo University and a business degree from INSEAD in France. He previously served on the boards of The Glaucoma Research Foundation and the National Alliance of Eye and Vision Research and is currently a board adviser for the University of California Irvine Research Center.
Kelly Webber has more than 35 years of Human Resources experience in companies with strong reputations for their HR capabilities.
At Bausch + Lomb, Ms. Webber leads the global Human Resources function with responsibility for developing and executing Human Resource strategy in support of the company’s overall business plan and strategic priorities.
Ms. Webber began her career at Citibank, where she held several positions of increasing responsibility for 16 years from 1985 to 2001, serving ultimately as the Vice President of the Global Consumer Internet business.
After Citibank, she joined Medco Health Solutions (now Express Scripts/Evernorth) as the Vice President of Corporate Human Resources and Talent Management from 2001 to 2012.
Immediately prior to joining Bausch + Lomb, Ms. Webber was the Chief Human Resources Officer of Bausch Health from 2016 to 2022 and Vice President of U.S. Human Resources from 2013 to 2016.
Ms. Webber holds a Bachelor of Science in Criminal Justice from Marist College.
Dr. Louis Yu has more than 40 years of leadership experience in the Quality and R&D functions of pharmaceutical and device companies. At Bausch + Lomb, Dr. Yu is responsible for strategic leadership and accountability for global quality and GXP compliance of regional regulatory authorities and health ministries around the world.
Previously, Dr. Yu served as Chief Quality Officer at Bausch Health from 2016 to 2022. Prior to that, he was Executive Vice President, Global Quality & Compliance, at The Perrigo Company from 2006 to 2016, where he was responsible for strategic leadership and regulatory compliance and the global patient safety/medical affairs departments. Following Perrigo and prior to joining Bausch Health, Dr. Yu served as the Senior Vice President, Global Quality and Compliance at AMRI, a contract development and manufacturing organization company.
Earlier in his career, Dr. Yu served as the highest Quality Officer for CV Therapeutics, Forest Laboratories and Solvay Pharmaceuticals USA. He also worked in the Quality and R&D organizations for more than 16 years at various Johnson & Johnson companies in positions of increasing responsibility.
Dr. Yu earned a Bachelor of Science in Chemistry from the University of Wisconsin and a Master of Science and Ph.D. in Analytical Chemistry from Rutgers University.
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.